BAIT
KRAS
C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, KI-RAS, KRAS1, KRAS2, NS, NS3, RASK2
Kirsten rat sarcoma viral oncogene homolog
GO Process (16)
GO Function (2)
GO Component (5)
Gene Ontology Biological Process
- Fc-epsilon receptor signaling pathway [TAS]
- MAPK cascade [TAS]
- Ras protein signal transduction [TAS]
- activation of MAPKK activity [TAS]
- axon guidance [TAS]
- blood coagulation [TAS]
- epidermal growth factor receptor signaling pathway [TAS]
- fibroblast growth factor receptor signaling pathway [TAS]
- innate immune response [TAS]
- insulin receptor signaling pathway [TAS]
- leukocyte migration [TAS]
- neurotrophin TRK receptor signaling pathway [TAS]
- positive regulation of cell proliferation [IMP]
- positive regulation of gene expression [IMP]
- positive regulation of protein phosphorylation [IMP]
- small GTPase mediated signal transduction [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
PREY
RXRA
NR2B1
retinoid X receptor, alpha
GO Process (13)
GO Function (14)
GO Component (5)
Gene Ontology Biological Process
- cellular lipid metabolic process [TAS]
- cholesterol metabolic process [TAS]
- gene expression [TAS]
- modulation by virus of host morphology or physiology [IDA]
- negative regulation of transcription from RNA polymerase II promoter [IDA]
- peroxisome proliferator activated receptor signaling pathway [IDA]
- positive regulation of transcription from RNA polymerase II promoter [IDA]
- protein homotetramerization [IDA]
- response to retinoic acid [IMP]
- retinoic acid receptor signaling pathway [IMP]
- small molecule metabolic process [TAS]
- transcription initiation from RNA polymerase II promoter [TAS]
- vitamin metabolic process [TAS]
Gene Ontology Molecular Function- DNA binding [IDA]
- RNA polymerase II regulatory region sequence-specific DNA binding [IDA]
- enzyme binding [IPI]
- ligand-activated sequence-specific DNA binding RNA polymerase II transcription factor activity [IDA]
- protein binding [IPI]
- protein heterodimerization activity [IDA]
- retinoic acid receptor activity [TAS]
- retinoic acid-responsive element binding [IDA]
- sequence-specific DNA binding [IDA]
- sequence-specific DNA binding transcription factor activity [IDA]
- transcription coactivator activity [TAS]
- transcription regulatory region DNA binding [IDA]
- vitamin D receptor binding [IPI]
- vitamin D response element binding [IDA]
- DNA binding [IDA]
- RNA polymerase II regulatory region sequence-specific DNA binding [IDA]
- enzyme binding [IPI]
- ligand-activated sequence-specific DNA binding RNA polymerase II transcription factor activity [IDA]
- protein binding [IPI]
- protein heterodimerization activity [IDA]
- retinoic acid receptor activity [TAS]
- retinoic acid-responsive element binding [IDA]
- sequence-specific DNA binding [IDA]
- sequence-specific DNA binding transcription factor activity [IDA]
- transcription coactivator activity [TAS]
- transcription regulatory region DNA binding [IDA]
- vitamin D receptor binding [IPI]
- vitamin D response element binding [IDA]
Gene Ontology Cellular Component
Homo sapiens
Negative Genetic
Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.
Publication
Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer.
CRISPR-based cancer dependency maps are accelerating advances in cancer precision medicine, but adequate functional maps are limited to the most common oncogenes. To identify opportunities for therapeutic intervention in other rarer subsets of cancer, we investigate the oncogene-specific dependencies conferred by the lung cancer oncogene, RIT1. Here, genome-wide CRISPR screening in KRAS, EGFR, and RIT1-mutant isogenic lung cancer cells identifies ... [more]
Nat Commun Dec. 09, 2020; 12(1);4789 [Pubmed: 34373451]
Throughput
- High Throughput
Ontology Terms
- growth abnormality (HP:0001507) [viability (PATO:0000169)]
Additional Notes
- CRISPR GI screen
- Cell Line: PC9-Cas9-KRASG12V
- Experimental Setup: Negative selection in the presence of 40 nM erlotinib
- GIST: A-phenotypic negative genetic interaction
- Library: Brunello Library
- Significance Threshold:
- CS
- >0.5 and p<0.05
Curated By
- BioGRID